/KRTX

KRTX Stock - Karuna Therapeutics, Inc.

Q: What is the analyst price target for KRTX?

Analyst price target information is not currently available for KRTX.

Q: What is KRTX's market cap?

Market capitalization information is not currently available for KRTX.

Healthcare|Biotechnology|NASDAQ

$329.83+0.03%

+$0.09 (+0.03%) • Mar 15

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-21.9%upside

Target: $257.60

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for KRTX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.15

52W High$329.99

52W Low$158.38

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$654,000	$10.64M	$36.96M	N/A	N/A
Gross Profit	$-1,047,000	$9.53M	$36.46M	$-145,000	$-58,000
Gross Margin	-160.1%	89.5%	98.6%	N/A	N/A
Operating Income	$-494,777,000	$-289,676,000	$-143,853,000	$-71,816,000	$-45,405,000
Net Income	$-433,680,000	$-276,336,000	$-143,805,000	$-68,554,000	$-44,844,000
Net Margin	-66311.9%	-2597.9%	-389.0%	N/A	N/A
EPS	$-11.73	$-8.74	$-4.94	$-2.59	$-3.75

Company Overview

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

67%

Hold / Neutral

33%

Sell / Underperform

Analyst Consensus🟡 Mixed

4 Bullish2 Neutral/Bearish

Price Targets

$243

Average Target

↓ 26.3% Downside

Now

$170

Low

$243

Average

$291

High

Based on 9 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 12th 2023	Citigroup	Initiation	Buy	$291
December 12th 2023	Deutsche Bank	Initiation	Buy	$227
August 22nd 2023	Wells Fargo	Initiation	Overweight	$225
July 20th 2023	Morgan Stanley	Initiation	Overweight	$280
March 8th 2023	Cantor Fitzgerald	Initiation	Neutral	$214
January 27th 2023	UBS	Initiation	Neutral	$209
January 5th 2023	Piper Sandler	Initiation	Overweight	$285
November 1st 2022	Loop Capital	Initiation	Buy	$288
July 14th 2022	SVB Leerink	Initiation	Outperform	$170

Earnings History & Surprises

KRTX

Beat Rate

65%

Last 20 quarters

Avg Surprise

+2.3%

EPS vs Estimate

Beats / Misses

13/7

Last 12 quarters

Latest EPS

$-2.80

Q2 2024

EPS Surprise History

Q3 22

-7.4%

$-2.17vs$-2.02

Q4 22

-19.6%

$-2.38vs$-1.99

Q1 23

+0.4%

$-2.22vs$-2.23

Q2 23

+2.1%

$-2.80vs$-2.86

Q3 23

+0.4%

$-2.75vs$-2.76

Q4 23

-15.3%

$-3.16vs$-2.74

Q1 24

-14.0%

$-3.01vs$-2.64

Q2 24

+8.5%

$-2.80vs$-3.06

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 2, 2024	$-3.06	$-2.80	+8.5%	✓ BEAT
Q1 2024	Feb 22, 2024	$-2.64	$-3.01	-14.0%	✗ MISS
Q4 2023	Nov 2, 2023	$-2.74	$-3.16	-15.3%	✗ MISS
Q3 2023	Aug 3, 2023	$-2.76	$-2.75	+0.4%	✓ BEAT
Q2 2023	May 4, 2023	$-2.86	$-2.80	+2.1%	✓ BEAT
Q1 2023	Feb 23, 2023	$-2.23	$-2.22	+0.4%	✓ BEAT
Q4 2022	Nov 3, 2022	$-1.99	$-2.38	-19.6%	✗ MISS
Q3 2022	Aug 8, 2022	$-2.02	$-2.17	-7.4%	✗ MISS
Q2 2022	May 5, 2022	$-2.06	$-1.95	+5.3%	✓ BEAT
Q1 2022	Feb 24, 2022	$-1.52	$-0.94	+38.2%	✓ BEAT
Q4 2021	Nov 4, 2021	$-1.40	$-1.72	-22.9%	✗ MISS
Q3 2021	Aug 5, 2021	$-1.24	$-1.17	+5.6%	✓ BEAT
Q2 2021	May 6, 2021	$-1.06	$-1.10	-3.8%	✗ MISS
Q1 2021	Feb 25, 2021	$-0.91	$-0.89	+2.2%	✓ BEAT
Q4 2020	Nov 5, 2020	$-0.76	$-0.71	+6.6%	✓ BEAT
Q3 2020	Aug 5, 2020	$-0.44	$-0.65	-47.7%	✗ MISS
Q2 2020	May 7, 2020	$-0.45	$-0.33	+26.7%	✓ BEAT
Q1 2020	Mar 24, 2020	$-0.47	$-0.32	+31.9%	✓ BEAT
Q4 2019	Nov 7, 2019	$-0.51	$-0.39	+23.5%	✓ BEAT
Q3 2019	Aug 8, 2019	$-0.87	$-0.65	+25.3%	✓ BEAT

Frequently Asked Questions about KRTX

What is KRTX's current stock price?

Karuna Therapeutics, Inc. (KRTX) is currently trading at $329.83 per share. The stock has moved +0.03% today.

What is the analyst price target for KRTX?

The average analyst price target for KRTX is $257.50, based on 1 analyst.

What sector is Karuna Therapeutics, Inc. in?

Karuna Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is KRTX's market cap?

Karuna Therapeutics, Inc. has a market capitalization of $12.60 billion, making it a large-cap company.

Does KRTX pay dividends?

No, Karuna Therapeutics, Inc. does not currently pay a dividend to shareholders.